PriceTargets.com logo

Protagonist Therapeutics - PTGX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $65.44
  • Forecasted Upside: 41.78%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$46.16 As of 04/23/2025 05:00 PM ET
▲ +0.31 (0.68%)

This chart shows the closing price for PTGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMarApr$45.85Closing price on 04/22/25:
Get New Protagonist Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTGX

Analyst Price Target is $65.44
▲ +41.78% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $65.44, with a high forecast of $80.00 and a low forecast of $38.00. The average price target represents a 41.78% upside from the last price of $46.16.

This chart shows the closing price for PTGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/254/255/26$17$33$49$64$80Closing price on 04/22/25: $45.85High$80.00Average$65.44Low$38.00




Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Protagonist Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/28/2025WedbushReiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00
3/11/2025WedbushReiterated RatingOutperform ➝ Outperform$70.00
3/11/2025Truist FinancialBoost TargetBuy ➝ Buy$60.00 ➝ $76.00
3/11/2025BMO Capital MarketsBoost TargetOutperform ➝ Outperform$62.00 ➝ $72.00
3/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$54.00 ➝ $54.00
3/4/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$53.00 ➝ $57.00
3/3/2025BTIG ResearchSet Target$73.00
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$54.00 ➝ $54.00
2/24/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$43.00 ➝ $38.00
2/24/2025HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $54.00
2/21/2025WedbushReiterated RatingOutperform$58.00
2/7/2025JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$58.00 ➝ $58.00
2/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
2/4/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$51.00 ➝ $53.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
12/6/2024The Goldman Sachs GroupInitiated CoverageNeutral$47.00
12/6/2024BMO Capital MarketsInitiated CoverageOutperform$62.00
12/5/2024The Goldman Sachs GroupUpgradeHold
11/19/2024WedbushReiterated RatingOutperform$58.00
11/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
11/4/2024WedbushReiterated RatingOutperform$58.00
9/25/2024TD CowenUpgradeStrong-Buy
9/24/2024TD CowenInitiated CoverageBuy$65.00
9/12/2024HC WainwrightBoost TargetBuy ➝ Buy$40.00 ➝ $50.00
9/9/2024Truist FinancialInitiated CoverageBuy$60.00
8/7/2024HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $40.00
8/7/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$45.00 ➝ $43.00
7/25/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$39.00 ➝ $48.00
7/24/2024BTIG ResearchBoost TargetBuy ➝ Buy$41.00 ➝ $51.00
6/17/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$45.00 ➝ $45.00
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00 ➝ $38.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00
5/8/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $45.00
2/28/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$34.00 ➝ $37.00
2/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$38.00
11/3/2023JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$35.00 ➝ $37.00
10/30/2023Capital One FinancialInitiated CoverageOverweight$32.00
10/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$38.00
9/25/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$36.00 ➝ $34.00
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$38.00
7/6/2023JMP SecuritiesBoost Target$28.00 ➝ $35.00
3/16/2023JMP SecuritiesLower TargetMarket Outperform$31.00 ➝ $28.00
3/16/2023HC WainwrightBoost TargetBuy$33.00 ➝ $38.00
3/8/2023JMP SecuritiesBoost TargetMarket Outperform$21.00 ➝ $31.00
11/16/2022BTIG ResearchLower Target$41.00
11/10/2022HC WainwrightLower TargetBuy$50.00 ➝ $33.00
8/25/2022JMP SecuritiesInitiated CoverageOutperform$21.00
5/17/2022Piper SandlerLower TargetOverweight$60.00 ➝ $35.00
4/26/2022BTIG ResearchLower Target$55.00 ➝ $45.00
4/14/2022BTIG ResearchReiterated RatingBuy$55.00
2/11/2022BTIG ResearchInitiated CoverageBuy$55.00
11/15/2021JMP SecuritiesBoost TargetPositive ➝ Outperform$60.00 ➝ $70.00
10/13/2021JMP SecuritiesBoost TargetHold ➝ Outperform$47.00 ➝ $60.00
10/12/2021Leerink PartnersBoost TargetOutperform$35.00 ➝ $50.00
10/12/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$49.00 ➝ $55.00
10/11/2021Jefferies Financial GroupBoost TargetHold ➝ Buy$29.00 ➝ $60.00
10/11/2021Northland SecuritiesUpgradeMarket Perform ➝ Outperform$40.00
9/22/2021JMP SecuritiesLower TargetMarket Outperform$55.00 ➝ $47.00
9/20/2021HC WainwrightReiterated RatingBuy$60.00 ➝ $50.00
9/20/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00 ➝ $49.00
9/17/2021JMP SecuritiesReiterated RatingHold ➝ Buy$47.00 ➝ $55.00
8/6/2021HC WainwrightBoost TargetBuy$50.00 ➝ $60.00
8/5/2021Leerink PartnersBoost TargetOutperform$41.00 ➝ $50.00
7/30/2021Piper SandlerBoost TargetOverweight$53.00 ➝ $93.00
6/18/2021HC WainwrightBoost TargetBuy$36.00 ➝ $50.00
6/14/2021Northland SecuritiesBoost TargetOutperform$42.00 ➝ $47.00
5/24/2021JMP SecuritiesInitiated CoverageMarket Outperform$48.00
5/24/2021Northland SecuritiesInitiated CoverageOutperform$42.00
3/11/2021HC WainwrightBoost TargetBuy$33.00 ➝ $36.00
3/3/2021Leerink PartnersBoost TargetPositive ➝ Outperform$30.00 ➝ $41.00
1/6/2021JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
12/16/2020Piper SandlerInitiated CoverageOverweight$53.00
12/7/2020BMO Capital MarketsBoost Target$37.00 ➝ $46.00
9/18/2020HC WainwrightBoost TargetBuy$28.00 ➝ $33.00
7/15/2020Jefferies Financial GroupInitiated CoverageBuy$27.00
5/22/2020Leerink PartnersBoost TargetOutperform$17.00 ➝ $30.00
5/13/2020HC WainwrightReiterated RatingBuy$23.00 ➝ $28.00
5/11/2020NomuraBoost TargetBuy$29.00 ➝ $33.00
5/11/2020Nomura InstinetBoost TargetBuy$29.00 ➝ $33.00
(Data available from 4/23/2020 forward)

News Sentiment Rating

1.49 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2024
  • 15 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 24 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/24/2024
  • 26 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025
  • 11 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2025
  • 25 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
3/24/2025
  • 22 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2025

Current Sentiment

  • 22 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Protagonist Therapeutics logo
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More

Today's Range

Now: $46.16
Low: $45.73
High: $47.35

50 Day Range

MA: $45.17
Low: $35.09
High: $59.76

52 Week Range

Now: $46.16
Low: $24.22
High: $60.60

Volume

1,416,211 shs

Average Volume

851,394 shs

Market Capitalization

$2.83 billion

P/E Ratio

17.35

Dividend Yield

N/A

Beta

2.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Protagonist Therapeutics?

The following equities research analysts have issued research reports on Protagonist Therapeutics in the last year: BMO Capital Markets, BTIG Research, HC Wainwright, JMP Securities, JPMorgan Chase & Co., StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Co., and Wedbush.
View the latest analyst ratings for PTGX.

What is the current price target for Protagonist Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Protagonist Therapeutics in the last year. Their average twelve-month price target is $65.44, suggesting a possible upside of 41.8%. HC Wainwright has the highest price target set, predicting PTGX will reach $80.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $38.00 for Protagonist Therapeutics in the next year.
View the latest price targets for PTGX.

What is the current consensus analyst rating for Protagonist Therapeutics?

Protagonist Therapeutics currently has 1 hold rating, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTGX will outperform the market and that investors should add to their positions of Protagonist Therapeutics.
View the latest ratings for PTGX.

What other companies compete with Protagonist Therapeutics?

Other companies that are similar to Protagonist Therapeutics include Ascendis Pharma A/S, Moderna, Viatris, Qiagen and Roivant Sciences. Learn More about companies similar to Protagonist Therapeutics.

How do I contact Protagonist Therapeutics' investor relations team?

Protagonist Therapeutics' physical mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company's listed phone number is (510) 474-0170 and its investor relations email address is bkorb@soleburytrout.com. The official website for Protagonist Therapeutics is www.protagonist-inc.com. Learn More about contacing Protagonist Therapeutics investor relations.





Receive Protagonist Therapeutics News & Ratings Daily
Sign up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with PriceTargets.com’s free daily newsletter.